CJC-1295 / Ipamorelin Side Effects: What the Research Shows

By DoseGauge Editorial · Updated 2026-06-13 · 7 min read

There is no FDA label for CJC-1295 or Ipamorelin, and the published human safety data are limited. That matters here more than anywhere else, because a definitive side-effect list normally comes from a prescribing document that an agency has reviewed, and no such document exists for either peptide. What follows is not that. It is what small studies and the growth-hormone-secretagogue drug class indicate, with that limitation stated plainly. It is informational and educational only, not medical advice, and it does not recommend either peptide or any dose. For background on what these compounds are, see what it is.

Why there is no official side-effect list

For an FDA-approved drug, the side-effect section comes from a prescribing document. A regulator has reviewed clinical trial data, the manufacturer has reported adverse events at known frequencies, and the result is a label you can cite. CJC-1295 and Ipamorelin are research peptides. Neither is approved by the FDA for human use, so there is no prescribing information, no agency-reviewed adverse-event table, and no validated list of side effects with frequencies attached.

That is the honest starting point. Anyone presenting a confident, label-style list of CJC-1295 / Ipamorelin side effects, complete with percentages, is presenting something that does not exist in the regulatory record. The published human data on these peptides are limited, and the studies that do exist were designed to look at growth hormone and IGF-1 response, not to build a complete safety profile. So the accurate framing is qualitative: what small studies observed, and what the drug class predicts, with the gaps named rather than filled in.

What the research and the drug class indicate

Two kinds of information are available, and it helps to keep them separate.

The first is injection-related. Both peptides are injected subcutaneously, and injection-site reactions (redness, itching, swelling, or soreness at the spot) are a common-sense expectation for any subcutaneous peptide. This is not specific to CJC-1295 or Ipamorelin; it follows from the route of administration.

The second is the growth-hormone-mediated class effect. CJC-1295 and Ipamorelin work by prompting the body to release more of its own growth hormone, which in turn raises IGF-1. In a single-injection study in healthy adults, CJC-1295 produced prolonged, several-day elevation of growth hormone and IGF-1 (Teichman et al., 2006). Raising growth hormone and IGF-1 is associated with known class effects, and the ones most often discussed are fluid retention and changes in insulin sensitivity and blood glucose. Headache and flushing are also commonly reported in connection with growth-hormone-secretagogue use.

The critical caveat: these are class-level and study-level observations, described qualitatively. They are not documented adverse-event rates for this blend, because no such rates exist. Notably, the Teichman trial of CJC-1295 reported that the compound was relatively well tolerated and that no serious adverse reactions occurred, but a small early-stage study like that cannot stand in for the long-term, large-population safety data an approved drug would have. Treat the class effects as reasons for caution and for clinical oversight, not as a settled count of who experiences what.

Ipamorelin's selectivity

One feature of Ipamorelin is worth singling out, because it shapes part of its side-effect picture. Ipamorelin was introduced as the first selective growth hormone secretagogue, with a selectivity for growth hormone release similar to that of GHRH (Raun et al., 1998).

What "selective" means here is specific. Earlier, non-selective secretagogues such as GHRP-6 and GHRP-2 raised ACTH and cortisol when they stimulated growth hormone. In the original work, Ipamorelin did not: it did not release ACTH or cortisol at levels significantly different from those seen after GHRH, and that held even at doses far above the dose needed for growth hormone release (Raun et al., 1998). The same study reported that none of the secretagogues it tested, Ipamorelin included, affected prolactin, FSH, LH, or TSH. So the precise claim is that Ipamorelin avoided the ACTH and cortisol rise that defined the non-selective compounds, not that it uniquely spared prolactin.

Why this matters for side effects: a secretagogue that also drives cortisol carries the additional concerns that come with raising a stress hormone. Ipamorelin's selectivity means that, in the animal work that introduced it, that particular pathway was not triggered. That is a meaningful distinction, but it is an animal finding about one peptide, and it does not establish a full human safety profile or speak to the long-term effects of the blend as it is sold.

The biggest limitation: missing long-term data

The most important thing to say about CJC-1295 / Ipamorelin side effects is what is missing. There are no long-term human safety studies of these peptides, and there is no study of the combined blend over time in a population large enough to characterize uncommon or delayed effects. The absence of that data is not reassurance. It is itself a risk, because effects that take months or years to appear, or that show up only in a fraction of users, are exactly the kind that short, small studies cannot detect.

This is why the page does not, and cannot, tell you these peptides are safe. The honest position is that the long-term human safety of CJC-1295 and Ipamorelin is not established, that they are not FDA-approved, and that the published data are limited. DoseGauge does not assess safety, and the calculator on this site does not either; it performs reconstitution and unit math on the values you enter and makes no judgment about whether a dose, or a compound, is appropriate for you. Whether any peptide is appropriate for a specific person is a clinical question for a licensed clinician.

Frequently asked questions

What are the side effects of CJC-1295 / Ipamorelin?

There is no FDA label, so there is no agency-reviewed list with frequencies. From small studies and the growth-hormone-secretagogue drug class, the effects commonly discussed are injection-site reactions, water retention and other fluid effects, headache, and flushing, along with the growth-hormone-mediated possibility of changes in blood glucose and insulin sensitivity. These are qualitative, class-level and study-level observations, not documented adverse-event rates for this blend, and the long-term human safety of these peptides is not established.

Does Ipamorelin raise cortisol?

In the study that introduced it, Ipamorelin did not raise cortisol or ACTH at levels significantly different from GHRH, even at doses far above the amount needed to release growth hormone (Raun et al., 1998). That is what made it the first selective growth hormone secretagogue, in contrast to non-selective compounds like GHRP-6 and GHRP-2, which did raise ACTH and cortisol. That finding comes from animal work and characterizes the peptide's selectivity; it does not establish a complete human safety profile.

Is CJC-1295 / Ipamorelin safe?

This page cannot call it safe. The human safety data on CJC-1295 and Ipamorelin are limited, neither peptide is FDA-approved for human use, and there are no long-term human safety studies of them or of the blend. That combination means the risks are not well characterized, which is different from saying the risks are low. A safety question about a specific person is a clinical question for a licensed clinician.

Does it affect blood sugar?

Possibly, because of how it works. CJC-1295 and Ipamorelin raise the body's own growth hormone and, downstream, IGF-1, and effects on insulin sensitivity and blood glucose are a recognized growth-hormone-mediated class concern. There is no FDA label quantifying this for the blend, so it cannot be stated as a documented rate, but it is one reason these peptides warrant clinical oversight. Discuss blood-sugar effects with a licensed clinician, especially if you have any glucose or insulin condition.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.